Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue D Pedersen

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Appetite|February 9, 2010
Comparison of 150-mm versus 100-mm visual analogue scales in free living adult subjectsJean-Philippe Chaput, Jo-Anne Gilbert, Nikolaj T Gregersen, et al.
Postgraduate Medicine|November 15, 2021
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practiceSean Wharton, Melanie Davies, Dror Dicker, et al.
The American Journal of Clinical Nutrition|June 10, 2016
A weight-loss program adapted to the menstrual cycle increases weight loss in healthy, overweight, premenopausal women: a 6-mo randomized controlled trialNina Rw Geiker, Christian Ritz, Sue D Pedersen, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|November 16, 2023
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonistsRonald M Goldenberg, Jeremy D Gilbert, Priya Manjoo, et al.
Current Opinion in Cardiology|April 30, 2021
The role of icosapent ethyl in cardiovascular risk reductionRonald M Goldenberg, Alice Y Y Cheng, Jeremy D Gilbert, et al.
Lancet (London, England)|June 29, 2023
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trialVanita R Aroda, Jens Aberle, Lars Bardtrum, et al.
Diabetes, Obesity & Metabolism|January 10, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trialsDomenica M Rubino, Sue D Pedersen, Lisa Connery, et al.
Lancet (London, England)|June 26, 2023
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialJuan P Frias, Srikanth Deenadayalan, Lars Erichsen, et al.
Diabetes, Obesity & Metabolism|May 29, 2023
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programmeSue D Pedersen, Francesco Giorgino, Guillermo Umpierrez, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 8, 2025
Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 yearsMarwan Sabbagh, Cristina Boschini, Sharon Cohen, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Appetite|February 9, 2010
Comparison of 150-mm versus 100-mm visual analogue scales in free living adult subjectsJean-Philippe Chaput, Jo-Anne Gilbert, Nikolaj T Gregersen, et al.
Postgraduate Medicine|November 15, 2021
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practiceSean Wharton, Melanie Davies, Dror Dicker, et al.
The American Journal of Clinical Nutrition|June 10, 2016
A weight-loss program adapted to the menstrual cycle increases weight loss in healthy, overweight, premenopausal women: a 6-mo randomized controlled trialNina Rw Geiker, Christian Ritz, Sue D Pedersen, et al.
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|November 16, 2023
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonistsRonald M Goldenberg, Jeremy D Gilbert, Priya Manjoo, et al.
Current Opinion in Cardiology|April 30, 2021
The role of icosapent ethyl in cardiovascular risk reductionRonald M Goldenberg, Alice Y Y Cheng, Jeremy D Gilbert, et al.
Lancet (London, England)|June 29, 2023
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trialVanita R Aroda, Jens Aberle, Lars Bardtrum, et al.
Diabetes, Obesity & Metabolism|January 10, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trialsDomenica M Rubino, Sue D Pedersen, Lisa Connery, et al.
Lancet (London, England)|June 26, 2023
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialJuan P Frias, Srikanth Deenadayalan, Lars Erichsen, et al.
Diabetes, Obesity & Metabolism|May 29, 2023
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programmeSue D Pedersen, Francesco Giorgino, Guillermo Umpierrez, et al.
Alzheimer'S & Dementia (New York, N. Y.)|May 8, 2025
Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 yearsMarwan Sabbagh, Cristina Boschini, Sharon Cohen, et al.
Pageof 4